Jiang Li-Xin, Li Xi, Li Jing, Feng Fang, Chen Yi-Ping, Chen Zheng-Ming, Martin Landray, Jane Armitage
China Oxford Centre for International Health Research Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China; On Behalf of HPS2-THRIVE China Collaborative Group. Email:
Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Aug;31(8):925-8.
To investigate the degree and determinants of the use on statin among patients with atherosclerotic ischemic stroke in China.
In the context of an international multi-center clinical trial being undertaken in China, 5585 patients with atherosclerotic ischemic stroke were screened in 39 prestigious hospitals in 10 cities. The characteristics collected through electronic questionnaire were described and analyzed.
All the screened patients had indications for statins. Among those, 60% of the patients had a history from 3 months to 2 years of suffering from stroke. However, up to 80% of the patients were not using statins when screened. Even in those with statins, about 1/4 of the patients took statins for much shorter period than the history of stroke. The proportion using statins among IS patients with CHD was 4 times more than in those without CHD. Simvastatin and Atorvastatin were most commonly used.
Statins were greatly underused for secondary prevention among patients with atherosclerotic ischemic stroke in China. There was a large gap between evidence and practice. It remains a major challenge for healthcare professionals and policy makers to tackle this problem more positively.
探讨中国动脉粥样硬化性缺血性卒中患者他汀类药物的使用程度及影响因素。
在中国正在进行的一项国际多中心临床试验中，对10个城市39家知名医院的5585例动脉粥样硬化性缺血性卒中患者进行了筛查。对通过电子问卷收集的特征进行了描述和分析。
所有筛查患者均有使用他汀类药物的指征。其中，60%的患者有3个月至2年的卒中病史。然而，高达80%的患者在筛查时未使用他汀类药物。即使在使用他汀类药物的患者中，约1/4的患者服用他汀类药物的时间比卒中病史短得多。合并冠心病的缺血性卒中患者使用他汀类药物的比例是未合并冠心病患者的4倍。辛伐他汀和阿托伐他汀使用最为普遍。
在中国，动脉粥样硬化性缺血性卒中患者二级预防中他汀类药物的使用严重不足。证据与实践之间存在很大差距。医疗专业人员和政策制定者更积极地解决这一问题仍然是一项重大挑战。
